Anthony P. Adamis

CIK: 0001277479

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KLRS

Kalaris Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

KLRS
Kalaris Therapeutics, Inc.
Jun 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
9K shares-
KLRS
Kalaris Therapeutics, Inc.
Apr 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18K shares-
KLRS
Kalaris Therapeutics, Inc.
Mar 18, 2025
Award(A)
Stock Option (right to buy)
Direct
19.5K shares-
KLRS
Kalaris Therapeutics, Inc.
Mar 18, 2025
Award(A)
Stock Option (right to buy)
Direct
13K shares-

		Type	Shares	Price		Ownership
Jun 3, 2026	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	9,000	-	-	Direct
Apr 10, 2025	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,000	-	-	Direct
Mar 18, 2025	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (right to buy)	19,484	-	-	Direct
Mar 18, 2025	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (right to buy)	12,989	-	-	Direct

1-4 of 4 transactions

About ADAMIS ANTHONY P

ADAMIS ANTHONY P (SEC CIK 0001277479) files insider reports with the SEC as Director of Kalaris Therapeutics, Inc. (KLRS).

Signal8 holds 4 ownership filings by ADAMIS ANTHONY P (1 Form 3, 3 Form 4), filed between Mar 18, 2025 and Jun 4, 2026. Those filings report 4 transactions, from Mar 18, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on ADAMIS ANTHONY P's filings is in BERKELEY HEIGHTS, NJ.

Recent filings by ADAMIS ANTHONY P

Jun 3, 2026: Grant or award of KLRS derivative securities (Form 4, code A).
Apr 10, 2025: Grant or award of KLRS derivative securities (Form 4, code A).
Mar 18, 2025: Grants or awards of KLRS derivative securities (2 lines, Form 4, code A).

Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)

Vandekop Amy O'Leary, VP, Corporate Controller
KEATING LAURIE, Director
Bayko Liisa Ann, Chief Financial Officer
Jovan-Embiricos Morana, Director
Ferrara Napoleone, Director
Hallal David, Director

How to read Form 4 transaction codes